← All trials
NCT04970108
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- May 31, 2024
- First posted
- Jul 21, 2021
- Last posted
- Jul 29, 2021
- Enrollment
- 320
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EMS S/ALead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.